Effect of grewia hirsuta vahl ethanolic root extract on cognition in scopolamine induced amnesia

Yamini  Y; Pushpa kumari B; Mehathaj S; Phani deepthi V

doi:10.37022/jpmhs.v4i4.49

Authors

N.Yamini Department of Pharmacology, Sri Padmavathi School of Pharmacy
B.Pushpa kumari Department of Pharmacology, Sri Padmavathi School of Pharmacy
S.Mehathaj Department of Pharmacology, Sri Padmavathi School of Pharmacy
V.Phani deepthi Department of Pharmaceutics, Oil Technological Pharmaceutical Research Sciences, JNTUA

DOI:

https://doi.org/10.37022/jpmhs.v4i4.49

Keywords:

Alzheimer’s diseases, memory enhancing, Scopolamine

Abstract

Objective Alzheimer's illnesses are becoming medical nightmares because there is no exact solution and existing nootropic medicines (Piracetam, tacrine, and metrifonate) have significant drawbacks. The goal of this study was to see if the ethanolic root extract of Grewia hirsuta (ERGH) could improve memory in rats who had been given scopolamine.

Materials and procedures At rats, ERGH was given orally in dosages of 200 and 400 mg/kg for 28 days, followed by Scopolamine (18 mg/kg i.p.) from the 25th to the 27th day. The usual nootropic drug was piracetam (200 mg/kg). The elevated plus maze (EPM), Morris water maze (MWM), and passive avoidance (PA) paradigms are used to assess cognitive functioning. Invivo anti-oxidant activity and brain acetylcholine esterase (AchE) activity were assessed.

Results: At the indicated doses, ERGH extract showed a substantial memory-enhancing activity by decreasing the transfer latency in EPM, increasing the escape latency in MWM, and increasing the shock-free zone in PA. In scopolamine-induced amnesia rats, pretreatment with ERGH resulted in a significant drop in AchE enzyme, an increase in enzymatic antioxidant, and a decrease in MDA levels.

Conclusion Because of its several favorable benefits, such as memory-improving properties, anticholinesterase activity, and antioxidant activity, ERGH may prove to be a useful drug in the current study, and it would be important to investigate its potential in the care of Alzheimer's patients.

Downloads

Download data is not yet available.

References

Ringman JM and Cummings JL, Current and emerging pharmacological treatment options for dementia, Behavneurol, 17(2006)5.

Lanni C, Lenzken SC and Pascale A, Cognition enhancers between treating and doping the mind, Pharmacol Res, 57(2008) 196.

Jewart, R. D., Green, J., Lu, C. J., Cellar, J. and Tune, L. E. (2005). Cognitive, behavioural, and physiological changes in Alzheimer disease patients as a function of incontinence medications. Am J Geriatr Psychiatry. 13: 324-328

Fratiglioni L, Winblad B, Strauss EV.Prevention of Alzheimer’s disease and dementia. Major findings from the Kungsholmen project. Physiol behavioural 2007; 92-98-104.

Blokland A.Acetylcholine: A neurotransmitter for learning and memory. Brain Res Rev 1996; 21:285-300.

Hock FJ. Therapeutic approaches for memory impairement. Behav brain Res 1995; 66:143-50.

Ringam JM, Cummings JL.Metrifonate: Update on a new antidementia agent, J Clin Psychiatry 1999; 60:776-82.

Joshi H, Parle M. Brahmi rasayana improves learning and memory in mice. Evid Based Complement Alternat Med 2006; 3:79-85.

Vasudevan M, Parle M, Pharmacological actions of Thespesia Populanea relevant to Alzheimer’s diseases.Phytomedicine 2006;13:677-87.

Morris R: Developments of a water-maze procedure for studying spatial learning in the rat. J Neurosci Methods, 1984, 11, 47–60.

Turner RA. Depressants of the central nervous system .Screening methods in Pharmacology.New York:Academic press;1965.p.78.

Voss G, Sachsse K. Red cell and plasma cholinesterase activities in microsamples of human and animal blood determined simultaneously by a modified acetylcholine/DTNB procedure. Toxicol Appl Pharmacol 1970; 16:764-72.

Lowry OH, Rosenburg NJ, Farr AL, Randale RJ. Protein measurement with folin phenol reagent. J Biol Chem 1951; 193:265‑75.

Ellman GL. In: Tissue sulphhydryl groups. Arc Biochem Biophys 1959; 82:70‑3.

Kagiyama T, Kagiyama S, Phillips MI. Expression of angiotensin type 1 and 2 receptors in brain after transient middle cerebral artery occlusion in rats. Regul Pept 2003; 110:241‑7.

Okhawa H, Ohishi N, Yagi K. Assay of lipid peroxides